Notes:
- Quantity Limits: Yes

Initiation (new start) criteria: Non-formulary **sotorasib (Lumakras)** will be covered on the prescription drug benefit when the following criteria are met:
- Prescribed by hematology/oncology
- Patient is greater than or equal to 18 years of age
- Presence of a KRAS G12C mutation
- Patient has a diagnosis of one of the following:
    - Locally advanced or metastatic non-small cell lung cancer (NSCLC) **AND**
        - Has received at least one prior systemic treatment for NSCLC
    - Locally advanced or metastatic colorectal cancer (CRC) that is proficient mismatch repair (pMMR)/ microsatellite stable (MSS) (or patient is ineligible for or had progression on checkpoint inhibitor immunotherapy) **AND**
        - Has received at least two prior lines of treatment for CRC, at least one of which included either oxaliplatin or irinotecan **AND**
        - Will receive sotorasib in combination with either cetuximab or panitumumab
    - Locally advanced or metastatic pancreatic cancer **AND**
        - Has received at least 2 prior systemic treatments for pancreatic cancer **OR**
        - Has received 1 prior systemic treatment for pancreatic cancer that included gemcitabine AND are not fit to receive a second-line combinatorial chemotherapy regimen (e.g. 5-FU + leucovorin +/- liposomal irinotecan, CapeOx, FOLFIRI, etc.)

Criteria for *current Kaiser Permanente members* already taking the medication who have not been reviewed previously: Non-formulary **sotorasib (Lumakras)** will be covered on the prescription drug benefit when the following criteria are met:
- Prescribed by hematology/oncology
- Patient is greater than or equal to 18 years of age
- Patient has a KRAS G12C mutation
- Patient has a diagnosis of locally advanced or metastatic locally advanced or metastatic NSCLC, CRC, or pancreatic cancer

Criteria for *new members* entering Kaiser Permanente already taking the medication who have not been reviewed previously: Non-formulary **sotorasib**

kp.org

KAISER PERMANENTE®

(Lumakras) will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by hematology/oncology
- Patient is greater than or equal to 18 years of age
- Patient has a KRAS G12C mutation
- Patient has a diagnosis of locally advanced or metastatic NSCLC, CRC, or pancreatic cancer